NAUT Nautilus Biotechnology, Inc.
Laboratory Analytical Instruments · Nasdaq · SEC CIK 1808805 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY6.7%
TTM EPS YoY8.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-41.0%
ROA-33.5%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets21.7%
Debt / equity0.00x
Current ratio9.25x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.90x
Accruals ratio-3.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $41.11M | $50.48M | $47.25M | $37.67M | $29.35M |
| SG&A expense | $25.73M | $31.00M | $28.90M | $25.95M | $21.15M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$59.00M | -$70.78M | -$63.67M | -$57.92M | -$50.31M |
| EPS (basic) | -0.47 | -0.56 | -0.51 | -0.46 | -0.60 |
| EPS (diluted) | -0.47 | -0.56 | -0.51 | -0.46 | -0.60 |
| Weighted avg. shares (diluted) | 126.26M | 125.43M | 124.92M | 124.59M | 84.46M |
| Balance sheet | |||||
| Cash & equivalents | $12.39M | $28.65M | $20.40M | $115.48M | $186.46M |
| Short-term investments | $91.02M | $102.25M | $154.02M | $69.95M | $160.11M |
| Current assets | $105.96M | $132.83M | $176.84M | $187.21M | $349.22M |
| PP&E, net | $3.46M | $4.08M | $4.27M | $3.70M | $2.48M |
| Total assets | $191.11M | $242.74M | $305.56M | $350.05M | $398.45M |
| Current liabilities | $7.95M | $7.63M | $9.12M | $6.79M | $5.81M |
| Total liabilities | $34.14M | $34.01M | $40.21M | $35.13M | $34.87M |
| Shareholders' equity | $156.97M | $208.73M | $265.35M | $314.92M | $363.58M |
| Shares outstanding | 126.47M | 126.11M | 125.07M | 124.87M | 124.30M |
| Cash flow statement | |||||
| Operating cash flow | -$50.70M | -$59.15M | -$51.71M | -$45.81M | -$39.24M |
| Capital expenditure | $1.28M | $2.12M | $2.44M | $2.32M | $2.27M |
| Free cash flow | -$51.97M | -$61.27M | -$54.15M | -$48.13M | -$41.51M |
| Investing cash flow | $35.22M | $66.25M | -$43.73M | -$25.74M | -$138.96M |
| Financing cash flow | $214,000 | $1.14M | $368,000 | $562,000 | $327.45M |
| Depreciation & amortization | $1.70M | $2.00M | $1.85M | $1.22M | $1.02M |
| Stock-based compensation | $6.84M | $12.70M | $12.14M | $10.38M | $7.93M |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.